← Back to Search

CAR T-cell Therapy

chimeric antigen receptor (CAR) T cell therapy for Breast Cancer

Phase 1
Waitlist Available
Research Sponsored by Bellicum Pharmaceuticals
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up through phase 1 completion, up to 2 years
Awards & highlights

Study Summary

This trial is studying a new cancer treatment and whether it is safe and effective.

Eligible Conditions
  • Breast Cancer
  • Gastric Cancer
  • Solid Tumors

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~through phase 1 completion, up to 2 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and through phase 1 completion, up to 2 years for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Maximum tolerated dose (MTD) and/or recommended dose for expansion (RDE)
Proportion of subjects experiencing Dose Limiting Toxicities at increasing doses of BPX-603
Secondary outcome measures
Antitumor activity of BPX-603
Expansion of HER2-CAR T cells (vector copy number)
Persistence of HER2-CAR T cells (cell counts)

Trial Design

1Treatment groups
Experimental Treatment
Group I: HER2-targeted dual-switch CAR-T cellsExperimental Treatment1 Intervention
Subjects will receive one dose of BPX-603 on Day 1, followed by rimiducid IV infusion weekly (as tolerated) starting on Day 8 and continued until treatment discontinuation criteria are met.

Find a Location

Who is running the clinical trial?

Bellicum PharmaceuticalsLead Sponsor
27 Previous Clinical Trials
1,132 Total Patients Enrolled
2 Trials studying Breast Cancer
155 Patients Enrolled for Breast Cancer

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Are there still opportunities to participate in this medical study?

"According to the information presented on clinicaltrials.gov, this trial is still in need of participants and was initially published on December 7th 2020 before being amended on August 10th 2022."

Answered by AI

How many research centers are participating in this trial?

"8 medical sites have been chosen to conduct this research, including the John Theurer Cancer Center and Hackensack University Medical Center in New jersey. Additionally, there are locations for UCSD La Jolla and the University of Chicago in Illinois as well as other facilities scattered across the country."

Answered by AI

What adverse effects have been linked to CAR T cell therapy?

"CAR T cell therapy has limited evidence of safety and efficacy, thus it is assigned a score of 1 on the Power team's scale."

Answered by AI

What is the total enrolment figure for this research project?

"The trial requires 220 people who meet the prerequisites to join. These individuals will be recruited from clinical centres such as John Theurer Cancer Center, Hackensack University Medical Center in New jersey, and UCSD in La Jolla California."

Answered by AI

Who else is applying?

What state do they live in?
Arkansas
How old are they?
65+
What site did they apply to?
The University of Texas MD Anderson Cancer Center
What portion of applicants met pre-screening criteria?
Met criteria
Recent research and studies
clinicaltrials.govStudy
Safety and Activity Study of HER2-Targeted Dual Switch CAR-T Cells (BPX-603) in Subjects With HER2-Positive Solid Tumors
2020. "Safety and Activity Study of HER2-Targeted Dual Switch CAR-T Cells (BPX-603) in Subjects With HER2-Positive Solid Tumors". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT04650451.
~73 spots leftby Dec 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top